Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | CCR5 | P51681 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | GFER | P55789 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.58 |
| ▸ | CDK9 | P50750 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | PRKACA | P17612 | 3/20 | 0.55 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.55 |
| ▸ | GSK3B | P49841 | 3/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18250718 | 0.98 | GAA (0.64) | GAAALOX15CYP2D6CCR5ALDH1A1 | |
| SCHEMBL18250748 | 0.97 | CCR5 (0.58) | GAAALOX15CYP2D6CCR5ALDH1A1 | |
| SCHEMBL9673866 | 0.93 | CCR5 (0.60) | GAAALOX15CYP2D6CCR5ALDH1A1 | |
| SCHEMBL7587030 | 0.85 | CCR5 (0.54) | GAAALOX15CYP2D6CCR5ALDH1A1 | |
| SCHEMBL3732583 | 0.85 | CCR5 (0.64) | GAAALOX15CYP2D6CCR5LMNA | |
| SCHEMBL10219470 | 0.85 | CYP2D6 (0.54) | GAAALOX15CYP2D6CCR5ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4379304 | 0.84 | CCR5 (0.53) | GAAALOX15CYP2D6CCR5ALDH1A1 | |
| SCHEMBL763378 | 0.84 | JAK2 (0.53) | GAAALOX15CYP2D6CCR5ALDH1A1 | |
| SCHEMBL13545208 | 0.82 | CCR5 (0.51) | CYP2D6CCR5LMNAOPRM1OPRD1 | |
| Hydrochloric Acid SCHEMBL20958819 | 0.81 | ALDH1A1 (0.48) | GAAALOX15CYP2D6CCR5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9499529-B2 | Therapeutic uses of curcumin analogs for treatment of prostate cancer | CALIFORNIA STATE UNIVERSITY, FRESNO (US) | 2016-11-22 | — | — | US | disclosed |
| US-7855211-B2 | such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases | ELI LILLY AND COMPANY (US) | 2010-12-21 | — | — | US | disclosed |
| US-20100160340-A1 | such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases | ELI LILLY AND COMPANY | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160340-A1 | such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases | MKI67, PKD1, CCNI | GAA 1317/4885ALOX15 1568/4885CYP2D6 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.